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Background: Obesity and aggressive prostate cancer (PC) may be linked, but how local
peri-prostatic fat relates to tumour response following androgen deprivation therapy
(ADT) is unknown.
Objective: To test if peri-prostatic fat volume (PPFV) predicts tumour response to ADT.
Design, setting, and participants: We performed a retrospective study on consecutive
patients receiving primary ADT. From staging pelvic magnetic resonance imaging scans,
the PPFV was quantiﬁed with OsirixX 6.5 imaging software. Statistical (univariate and
multivariate) analysis were performed using R Version 3.2.1.
Results and limitations: Of 224 consecutive patients, 61 with advanced (T3 or N1 or
M1) disease had (3-mm high resolution axial sections) pelvic magnetic resonance
imaging scan before ADT. Median age = 75 yr; median PPFV = 24.8 cm3 (range, 7.4–
139.4 cm3). PPFV was signiﬁcantly higher in patients who developed castration resistant
prostate cancer (CRPC; n = 31), with a median of 37.9 cm3 compared with 16.1 cm3 (p
< 0.0001, Wilcoxon rank sum test) in patients who showed sustained response to ADT
(n = 30). Multivariate analysis using Cox proportional hazards models were performed
controlling for known predictors of CRPC. PPFV was shown to be independent of all
included factors, and the most signiﬁcant predictor of time to CRPC. Using our multi-
variate model consisting of all known factors prior to ADT, PPFV signiﬁcantly improved
the area under the curve of the multivariate models receiver operating characteristic
analysis. The main study limitation is a relatively small cohort to account for multiple
variables, necessitating a future large-scale prospective analysis of PPFV in advanced PC.
Conclusions: PPFV quantiﬁcation in patients with advanced PC predicts tumour
response to ADT.
Patient summary: The amount of fat around the prostate predicts prostate cancer
response to hormone treatment.
© 2017 European Association of Urology. Published by Elsevier B.V. This is an open access
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
* Corresponding author. The CRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61
1BD, Scotland, UK. Tel. +441413303658; Fax: +441419426521.
E-mail address: h.leung@beatson.gla.ac.uk (H.Y. Leung).1. Introduction
Prostate cancer (PC) is the most common cancer of men in
the developed world. Treatment for symptomatic advanced
or metastatic PC includes androgen deprivation therapyPlease cite this article in press as: Salji M, et al. Peri-prostatic F
Resistance in Advanced Prostate Cancer. Eur Urol Focus (2017), h
http://dx.doi.org/10.1016/j.euf.2017.01.019
2405-4569/© 2017 European Association of Urology. Published by Elsevie
creativecommons.org/licenses/by/4.0/).(ADT). All men receiving ADT eventually develop castration
resistant prostate cancer (CRPC) [1]. Despite recent
advances in second line chemotherapeutics, the median
survival has only improved by 2–5 mo [2–4]. Upfront doc-
etaxel therapy has shown a greater increase in survivalat Volume Measurement as a Predictive Tool for Castration
ttp://dx.doi.org/10.1016/j.euf.2017.01.019
r B.V. This is an open access article under the CC BY license (http://
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13.6 mo over ADT alone [5,6]. An initial poor response to
ADT with nadir prostate-specific antigen (nPSA) not falling
below 4 mg/ml is a predictor of early CRPC [1]. As both nPSA
and time to nPSA can only be calculated after ADT, there is
an urgent need for clinically impactful predictive markers
for the development of CRPC.
Epidemiological studies suggest an association between
higher body fat (as estimated by body mass index; BMI) and
earlier age of diagnosis and the risk of disease progression,
including CRPC [7–9]. Visceral fat is metabolically active and
may contribute to tumour promoting signalling in PC.
Intriguingly, adipocyte-mediated chemokine secretion as
part of a chemokine axis involving chemokine ligand 7
(CCL7) and its receptor chemokine receptor 3 (CCR3) may
mediate interactions between local peri-prostatic fat (PPF)
and PC to promote tumour progression [10–12]. Until
recently, evaluation of PPF as a predictive marker has been
limited to the analysis of either PPF thickness or area
(ie, 1- or 2-dimension measurements) in patients undergo-
ing radical prostatectomy or radical radiotherapy [13–16].
By accurately quantifying the volume of PPF in patients with
advanced PC prior to primary ADT, we tested if measuring
PPF volume improves the current prognostic tools in iden-
tifying patients who are at risk of developing CRPC, and
stratifies patients for enhanced monitoring or additional
therapy from the outset.
2. Patients and methods
2.1. Patient selection
Over a 2-yr period, consecutive patients with locally advanced or meta-
static PC treated with primary ADT were identiﬁed (n = 224). Patients
underwent staging investigations by computed tomography (n = 151) or
magnetic resonance imaging (MRI; n = 73) of the prostate and pelvis for
local disease staging along with isotopic bone scan. Of 73 patients with
MRI, the following patients were excluded for analysis: two due to lack of
follow up (moving out of region), one patient with T2 localised disease, and
nine with MRI after starting ADT. The majority were treated with luteinis-
ing hormone-releasing hormone analogues (n = 53) but also androgen
receptor blocker alone (n = 4), oestrogen patches (n = 3), or luteinising
hormone-releasing hormone antagonist (n = 1) were included.
2.2. Staging MRI analysis
Cases with T2-weighted pelvic MRI images at slice thicknesses of 3 mm
or less were studied. Peri-prostatic fat volume (PPFV) was calculated by
consecutive areas through the prostate, with the prostatic and seminal
vesicular volumes subtracted to give the PPFV (see details below).
Training for the recognition of PPF on T2-weighted MRI images was
provided by a single uro-radiologist experienced in prostate MRI. Regions
of interest were drawn on consecutive axial images by a single investi-
gator using OsiriX (Version 6.5, 2013 Pixmeo Sarl, Switzerland). Waist
circumference was measured using whole pelvis T2 axial images at
vertebral level L5.
2.3. PPFV measurement technique
PPFV measurements were blinded to CRPC status and made by initially
delineating the prostate gland and seminal vesicle. The surroundingPlease cite this article in press as: Salji M, et al. Peri-prostatic F
Resistance in Advanced Prostate Cancer. Eur Urol Focus (2017), hregion of PPF including vessels draining the prostate were then delin-
eated laterally by the ﬁrst visible fascial boundary adjacent to the levator
muscles, posteriorly by Denonvillier’s facia (excluding the mesorectal
fat) and anteriorly to the pubic symphysis, including the anterior venous
plexus and retropubic fat, on each 3-mm slice from the bladder neck
superiorly to prostate apex inferiorly. This delineated the region of
surrounding adipose tissue of similar signal and composition including
local vasculature providing venous drainage of the prostate and seminal
vesicles. Collectively, these represent the local visceral adipose-rich
tumour macro-environment.
2.4. Immunohistochemistry
Patients were grouped by their response to ADT into three groups: (1)
Favourable Sustained Response to ADT (SRADT) with PSA remaining at
nadir levels and below 4 ng/ml throughout the follow up period, (2)
Initial Response to ADT (IRADT) with PSA falling below 4 ng/ml but then
developing CRPC, and (3) Poor Response to ADT (PRADT) with nPSA not
falling below 4 ng/ml and subsequently developing CRPC. Formalin ﬁxed
parafﬁn embedded prostate tumour sections were obtained in accor-
dance with appropriate ethics approval (National Health Service
Research Ethics Committee permission: 12/EE/0058), including SRADT
(n = 6), IRADT (n = 6), and PRADT (n = 6). Sections were stained for CCR3
as a secondary outcome measure of PPFV inﬂuence on prostatic epithe-
lium (rabbit monoclonal antibody; Abcam, ab32512 1:50 dilution),
and signal ampliﬁed with Dako Rabbit EnVision (K4003) and visualised
using Dako Liquid 3,30-diaminobenzidine (DAB; K3468). Using the Leica
Biosystems Image Analysis suit (v4.0.6), DAB staining was quantiﬁed
by normalising the area of DAB staining to the area of haematoxylin
counterstain.
2.5. Data collection and statistical analysis
Demographic data including age, initial PSA, nPSA, evidence of (distant
and/or regional nodal) metastasis at the time of diagnosis, and time-to-
reach nPSA were recorded. Biochemical progression to CRPC as the
primary outcome measure was indicated by three successive rises in
PSA level after commencing ADT [17]. Where available Gleason score,
tumour stage, and presence of distant metastases and lymph node status
were included. Statistical analysis were performed in R (Version 3.2.1)
with signiﬁcance taken as p < 0.05 and indicated by *, p < 0.001 **,
p < 0.0001***. Univariate Cox proportional hazards models of time to
CRPC were performed for PPFV, metastasis (lymph node and/or distant)
at diagnosis, T stage, Gleason score, initial PSA, nPSA, body weight, and
waist circumference. Multivariate Cox proportional hazards models of
time to CRPC were performed with covariates PPFV, metastasis (lymph
node and/or distant) at diagnosis, T stage, Gleason score, initial PSA, and
body weight, excluding nadir PSA as this can only be known after
commencing ADT.
3. Results
Between January 2011 to December 2012, 224 patients
receiving primary ADT were identified. Among them,
61 patients had an MRI of the prostate and pelvis prior to
commencing ADT (median of 23 d prior to ADT). The
remaining 163 patients were excluded due to the use of a
staging computed tomography instead of MRI (n = 151), T2
localised disease (n = 1), lack of follow-up data due to
moving out of region (n = 2), or the MRI being performed
after commencing ADT (n = 9). Of the 61 patients analysed
(median age 75 yr), 36 patients (58%) had evidence of
metastases at diagnosis (stage range: T3N0M0-T4N1M1).at Volume Measurement as a Predictive Tool for Castration
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Table 1 – Cohort demographics and clinical parameters.
















Median 75 77 36.71 24.80 40.30 1.1 4 + 4 40
Min. 53 44 13.32 7.45 1.30 0.1 3 + 3 31
Max. 89 111 164.50 139.41 653.9 61.3 5 + 5 52
ADT = androgen deprivation therapy; Max. = maximum; Min. = minimum; PPF = peri-prostatic fat; PSA = prostate-speciﬁc antigen.
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prostate histology. Among patients with a reported Gleason
score, 31/50 patients (62%) had disease with a Gleason score
8. The median follow up was 40 mo (range, 31–52 mo;
Table 1).
3.1. PPFV is higher in patients who subsequently developed
CRPC
PPFV measurements ranged from 7.4 cm3 to 139.4 cm3
(Fig. 1 depicts examples of the highest and lowest PPFV
cases; median 24.8 cm3) and was significantly higher in
patients who developed CRPC within the study periodLow peri-prostatic fat volum
High peri-prostatic fat volum
Transverse T2 
Transverse T2
Fig. 1 – Pelvic magnetic resonance imaging scans of the lowest and highest pe
magnetic resonance imaging scans of the lowest PPFV (7.4 cm3) and highest PP
interest marked) and midline sagittal views (with cross-section reference line)
peri-prostatic fat in green.
Please cite this article in press as: Salji M, et al. Peri-prostatic F
Resistance in Advanced Prostate Cancer. Eur Urol Focus (2017), h(median of 37.9 cm3) than those with SRADT (median of
16.1 cm3, p < 0.0001, Wilcoxon Rank Sum test; Fig. 2A) and
unaffected by normalisation to prostate volume. PPFV
weakly correlated with initial PSA levels (rs = 0.26,
p = 0.04, Spearman’s Rank correlation), but not with time
to nPSA (rs = 0.04, p = 0.78), Gleason score (rs = 0.03,
p = 0.82) or tumour stage (rs = 0.08, p = 0.52). PPFV did
correlate with nPSA (rs = 0.45, p = 0.0003) and on further
stratification of patients with evidence of CRPC, patients
showing IRADT had lower PPFV than those with PRADT
(p = 0.006, Wilcoxon Rank Sum test; Fig. 2B). PPFV also
negatively correlated with time to CRPC (rs = 0.34,
p = 0.008, Spearman’s Rank correlation). As expected, nPSAe (7.4 cm3)
e (139.4 cm3)
Midline sagittal T2
Midline sagittal T2 
ri-prostatic fat volume (PPFV) cases. Examples of T2-weighted pelvic
FV (139.4 cm3) cases within our cohort. Transverse (with regions of
 are shown with the prostate highlighted in red and the surrounding
at Volume Measurement as a Predictive Tool for Castration
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Fig. 2 – (A) Peri-prostatic fat volume (PPFV) in patients who develop castration resistant prostate cancer (CRPC). PPFV in patients who developed CRPC
compared with patients with sustained response to androgen deprivation therapy (SRADT) with no evidence of rising prostate-specific antigen (PSA)
within the follow-up period (median 40 mo), showing significantly greater PPFV in patients who develop CRPC within the follow-up period. All Box
and Whisker diagrams middle bands represent the median value, the upper and lower box represents the upper and lower quartiles, whiskers extend
from the upper and lower quartiles by 1.5 T the interquartile range, individual patients are also plotted as solid black points overlaid on the boxplots
and laterally separated by a wrapping corral to avoid over-lay of same Y axis values. (B) PPFV in patients with initial response and poor response to
ADT (IRADT and PRADT). PPFV in patients who initially respond (IR) to ADT with a PSA drop below the normal range (4 ng/ml) but then develop CRPC
(IRADT) have greater PPFV than patients with a sustained response (SR) to ADT (SRADT) who did not develop CRPC within the follow-up period
(p < 0.001 Wilcoxon Rank Sum test). Patients who have PRADT by nadir PSA not falling below the normal range (4 ng/ml) appeared to have an even
higher PPFV (p = 0.006, Wilcoxon Rank Sum test). Individual patients are plotted as solid black points overlaid on the boxplots. (C and D) Analysis of
time to CRPC and its relationship to PPFV. Kaplan Meier analysis of time to CRPC for two groups of patients divided by the median PPFV (1C; n = 31 red
>24.8 cm3, n = 30 blue <24.8 cm3). Patients with higher PPFV showed greater and faster development of CRPC as shown by Kaplan-Meier curves over a
range of PPFV (1D).
*** p < 0.001.
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non-CRPC patients (median, 2.10 vs 0.40 respectively,
p = 0.0003, Wilcoxon Rank Sum test).
3.2. PPFV did not correlate to whole body measures
of adiposity
We found no correlation between PPFV and surrogate whole
body measures of adiposity such as body weight and waist
circumference (weight range: 44–111 kg, median 77 kg;
waist circumference range: 72–123 cm, median 93 cm;
rs = 0.13, p = 0.3, and rs = 0.17, p = 0.18, Spearman’s Rank
correlation). In this study, patient body weight did not
correlate with time to CRPC (rs = 0.02, p = 0.9, Spearman’s
Rank correlation), or response to ADT (PRADT; p = 0.3,
Wilcoxon Rank Sum test; Supplementary Fig. 1)Please cite this article in press as: Salji M, et al. Peri-prostatic F
Resistance in Advanced Prostate Cancer. Eur Urol Focus (2017), h3.3. PPFV significantly predicted the risk of developing CRPC
The impact of PPFV on time to CRPC is illustrated by a
Kaplan-Meier survival analysis (Fig. 2C), with the time to
CRPC significantly different between patients with above
and below the median PPFV (24.8 cm3). Furthermore, a dose
effect of the PPFV was observed with higher PPFV progres-
sively showing reducing time to CRPC when patients were
grouped according to their PPFV (0–15 cm3, 15–45 cm3,
>45 cm3; Fig. 2D).
Univariate Cox proportional hazards models of time to
development of CRPC were performed using factors of PPFV,
nPSA, evidence of (lymph node or distant) metastasis at
diagnosis, waist circumference, body weight, Gleason score,
initial PSA, BMI, and local T stage (Table 2). Factors were
initially considered in isolation, and PPFV, metastasis statusat Volume Measurement as a Predictive Tool for Castration
ttp://dx.doi.org/10.1016/j.euf.2017.01.019
Table 2 – Univariate analysis of known predictors of time to CRPC. Univariate Cox proportional hazards models of factors which may predict
castrate resistant prostate cancer (CRPC) in our cohort. Showing hazard ratios, 95% lower and upper confidence intervals, p value, and
number of observations. Factors have been ordered by their p value lowest to highest for their individual prediction of CRPC. Peri-prostatic
fat volume (PPFV), nadir prostate-specific antigen (PSA), metastasis at diagnosis, and nodal disease at diagnosis are all individually
significant predictors of CRPC. PPFV is grouped into 10 cm3 levels, metastasis at diagnosis is a binary factor (y/n), local T stage is divided into
levels (T1c, T2, T3, T3a, T3b and T4), Gleason score is a binary factor greater than 4 + 4 (y/n). PSA values, body weight, waist circumference, and
body mass index (BMI) are continuous variables.
Hazard ratio Lower conﬁdence interval Upper conﬁdence interval p value n
PPFV (10 cm3) 1.408 1.211 1.637 <0.0001*** 61
Nadir PSA (ng/ml) 1.058 1.023 1.095 0.00108** 59
Metastasis at diagnosis (y/n) 3.329 1.43 7.754 0.00529** 61
Lymph nodes at diagnosis (y/n) 2.617 1.168 5.865 0.0195* 59
Waist circumference (cm) 1.023 0.9887 1.059 0.189 61
Body weight (kg) 1.011 0.9842 1.039 0.418 60
Gleason score (>4 + 4) 0.8207 0.3765 1.789 0.619 50
BMI (Kg/m2) 1.039 0.8774 1.23 0.657 24
Local T stage (T1c–T4) 0.9638 0.7305 1.272 0.794 60
Initial PSA (ng/ml) 0.9998 0.9969 1.003 0.894 61
n = no; y = yes.
* p < 0.05.
** .
*** p < 0.0001.
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ever, in our cohort, whole body measures such as weight,
waist circumference, and BMI (when available) did not
individually predict CRPC (Table 2). Factors were then added
and removed sequentially to generate an optimised multi-
variate model consisting of PPFV and presence of metastasis
at diagnosis (Wald test = 24.7 on 2 degrees of freedom,Table 3 – Optimised multivariate analysis of predictors of time to castra
hazards model included only peri-prostatic fat volume (PPFV) and me
confidence intervals, p-value, and number of observations for PPFV and
improve the model (Wald test = 24.7 on 2 degrees of freedom, p = 4.325
Hazard ratio Lower conﬁdence i
PPFV (10 cm3) 1.380 1.183 
Metastasis at diagnosis (y/n) 3.059 1.299 
n = no; y = yes.
* p <0.05.
** p <0.0001.
Table 4 – Multivariate analysis of significant predictors of time to castr
model of peri-prostatic fat volume (PPFV), distant metastasis at diagn
(PSA). The optimised multivariate model of PPFV and metastasis at diag
diagnosis or nadir PSA. PPFV prediction of castrate resistant prostate ca
predicting factors on univariate analysis (distant metastasis or lymph 
freedom, p = 1.575e–05).
Hazard ratio Lower conﬁdenc
PPFV (10 cm3) 1.332 1.1198 
Metastasis at diagnosis (y/n) 2.495 0.8526
Lymph nodes at diagnosis (y/n) 2.081 1.168 
Nadir PSA (ng/ml) 1.021 0.9774 
n = no; y = yes.
* p < 0.05.
** p < 0.0001.
Please cite this article in press as: Salji M, et al. Peri-prostatic F
Resistance in Advanced Prostate Cancer. Eur Urol Focus (2017), hp = 4.325e–06; Table 3). A multivariate model was then
performed incorporating all previously identified signifi-
cant predictors of CRPC on univariate analysis (PPFV,
metastasis [lymph node and/or distant] at diagnosis, and
nPSA), showing that only PPFV and distant metastasis at
diagnosis were independent predictors of time to CRPC
(Table 4). Including tumour stage, Gleason score, waistte resistant prostate cancer. Optimised multivariate Cox proportional
tastasis at diagnosis. Showing hazard ratios, 95% lower and upper
 distant metastasis at diagnosis. Addition of further variables did not
e–06).
nterval Upper conﬁdence interval p value n
1.609 <0.00001** 61
7.206 0.0105* 61
ate resistant prostate cancer. Multivariate Cox proportional hazards
osis, lymph nodes at diagnosis, and nadir prostate-specific antigen
nosis was not improved by the additional factors of lymph nodes at
ncer remains independent after controlling for all other significantly
nodes at diagnosis and nadir PSA; Wald test = 27.5 on 4 degrees of
e interval Upper conﬁdence interval p value n
1.584 0.0012** 57
 5.080 0.0461* 57
5.865 0.1074 57
1.066 0.3570 57
at Volume Measurement as a Predictive Tool for Castration
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Table 5 – Multivariate analysis including expected predictors of time to castrate resistant prostate cancer (CRPC). Multivariate Cox
proportional hazards model of peri-prostatic fat volume (PPFV), distant metastasis at diagnosis, lymph nodes at diagnosis, nadir prostate-
specific antigen (PSA), Local T stage, Gleason score, waist circumference, and body weight. This multivariate model utilised previously
identified factors reported to predict CRPC. PPFV prediction of CRPC remained independent after controlling for other factors previously
predicting CRPC, however the model fit is not improved by them. (Wald test = 23.6 on 8 degrees of freedom, p = 0.002674).
Hazard ratio Lower conﬁdence interval Upper conﬁdence interval p value n
PPFV (10 cm3) 1.2773 1.0474 1.558 0.0157* 47
Metastasis at diagnosis (y/n) 1.5728 0.5472 4.520 0.4005 47
Nodes at diagnosis (y/n) 3.4844 1.1519 10.540 0.0271* 47
Nadir PSA (ng/ml) 1.0246 0.9710 1.081 0.3752 47
Local T stage (T1c–T4) 0.8560 0.5762 1.272 0.4416 47
Gleason score (>4 + 4) 0.8706 0.2970 2.552 0.8006 47
Waist circumference (cm) 1.0642 0.9861 1.148 0.1097 47
Body weight (kg) 0.9590 0.9053 1.016 0.1547 47
n = no; y = yes.
* p < 0.05.
Fig. 3 – Receiver operating characteristics analysis curves of peri-
prostatic fat volume (PPFV) added to current staging parameters known
prior to androgen deprivation therapy (ADT). Receiver operating
characteristics analysis of the multivariate model presented in Table 6
consisting of factors known at ADT (not including nadir prostate-
specific antigen). Upper curve (red) shows prediction of the multivariate
model in our cohort including PPFV with area under the curve (AUC)
= 88.4%. Removing PPFV from the multivariate model in Table 6
produces the lower curve and AUC is significantly reduced to 81.7%
(p = 0.02518, Delong’s test), suggesting a benefit of including PPFV in the
multivariate model of factors known prior to commencing ADT in order
to better predict the risk of developing castration resistant prostate
cancer.
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did not improve the model fit (Wald test = 23.6 on 8 degrees
of freedom, p = 0.002674; Table 5).
3.4. PPFV improved on current predictive factors known
prior to ADT
A multivariate Cox proportional hazards model was gen-
erated using the following factors that are known prior to
ADT: PPFV, (nodal and distant) metastasis status at diag-
nosis, local T stage, initial PSA, and body weight (Table 6).
The inclusion of PPFV into the panel significantly improved
the performance of the prognostic model, with signifi-
cantly better receiver operating characteristics area under
curve (AUC; 88.4% and 81.7%, respectively, Delong’s test
p = 0.025; Fig. 3). While Gleason score was not included in
the model due to the limitation of the missing values of
Gleason score in our cohort (11 out of 61 patients did not
have an initial Gleason score), the addition of Gleason
score in the model had little effect on the AUC (Supple-
mentary Fig. 3).
The first 13 consecutive MRI scans were also analysed by a
second observer to assess correlation and interobserver
agreement(Bland Altman)ofPPFVmeasures(Supplementary
Fig. 2). High correlation was observed between independent
measures: Two way intraclass correlation coefficient = 0.918,
(p < 0.001, 95% confidence interval: 0.755–0.974). The
median number of slices required for PPFV measurement
was 6 (range, 4–11), time required to calculate PPFV as
estimated to be 12 min (1 min  2 regions  6 slices) allow-
ing 1 minute per region of interest with two regions of
interest required for each slice (prostate and peri-prostatic
fat region).
3.5. CCR3 expression was upregulated in tumours associated
with high PPFV and CRPC
Immunohistochemistry for CCR3 was performed on pros-
tate biopsy materials on randomly selected patient subco-
horts according to their response to ADT: SRADT (n = 6),
IRADT (n = 6), and PRADT (n = 6). CCR3 immunoreactivity
was significantly upregulated in tumours from PRADTPlease cite this article in press as: Salji M, et al. Peri-prostatic F
Resistance in Advanced Prostate Cancer. Eur Urol Focus (2017), hpatients (p = 0.04, Wilcoxon Rank Sum test; Fig. 4A). There
was a trend for progressive increase in CCR3 expression
from low, medium, to high PPFV: low PPFV (<15 cc, n = 4),
medium PPFV (15–45 cc, n = 10), and high PPFV (<45 cc,
n = 4; low PPFV vs high PPFV, p = 0.057, Wilcoxon Rank Sum
test; Fig. 4B). CCR3 immunohistochemistry in low, medium,
and high PPFV patients are shown in Fig. 4C.at Volume Measurement as a Predictive Tool for Castration
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Table 6 – Multivariate model of factors known at the time of androgen deprivation therapy. Multivariate Cox proportional hazards model
was generated using only factors known at androgen deprivation therapy. The highest area under the curve (AUC) was calculated for the
predictive model including peri-prostatic fat volume (PPFV), metastasis at diagnosis, lymph nodes at diagnosis, local T stage, initial prostate-
specific antigen (PSA), and body weight. Receiver operating characteristic analysis of the predicted model produced AUC 88.4% (confidence
interval: 79.2–97.6%). PPFV removal from the multivariate model prediction significantly reduced the AUC to 81.7% (confidence interval:
70.56–92.88%, DeLong’s test p-value = 0.02518; Fig. 3).
Hazard ratio Lower conﬁdence interval Upper conﬁdence interval p value n
PPFV (10 cm3) 1.3949 1.1826 1.6452 <0.0001*** 58
Metastasis at diagnosis (y/n) 2.5702 1.5179 9.3923 0.00427** 58
Nodes at diagnosis (y/n) 3.3812 1.2910 7.4362 0.01135* 58
Local T stage (T1c–T4) 0.7093 0.4707 0.9100 0.01171* 58
Initial PSA (ng/ml) 0.9958 0.9922 0.9993 0.01798* 58
Body weight (kg) 1.0143 0.9757 1.0390 0.67004 58
n = no; y = yes.
* p < 0.05.
** p.
*** p < 0.0001.
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Our report, for the first time, links clinical imaging to
tumour-host interaction in the context of treatment resis-
tance, supporting a role for PPF in CRPC. It is also in line with
recent findings that local visceral fat functions through theFig. 4 – Analysis of chemokine receptor 3 (CCR3) immunohistochemistry (IHC)
prostate cancer (CRPC). (A) CCR3 stained area normalised by haematoxylin stai
who developed CRPC than patients who did not develop CRPC within the follo
[SRADT] vs initial response to ADT [IRADT] and partial response to ADT [PRADT
higher in patients with high PPFV (45 cm3, n = 4) compared with patients wit
between suggesting a dose effect (low PPFV vs high PPFV, p = 0.057, Wilcoxon R
(med) and high PPFV are also provided.
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measurement of PPFV in patients undergoing primary ADT
may help predict tumour response and the likelihood of
developing CRPC. These measurements can be performed
easily and reproducibly with basic training to recognise the
relevant anatomy on MRI. in relation to peri-prostatic fat volume (PPFV) and castration resistant
ned area (mm2; 3,30-diaminobenzidine+/H+) was greater for patients
w-up period (sustained response to androgen deprivation therapy
] p = 0.04, Wilcoxon Rank Sum test). (B) CCR3 staining tended to be
h a low PPFV (15 cm3, n = 4) with medium PPFV (15–45 cm3, n = 10) in-
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predictive factors of CRPC
In our cohort, initial PSA readings, tumour stage and high
Gleason score, body weight, and waist circumference were
not informative alone in predicting which patients will
initially respond well to ADT. This may simply reflect the
consequence of studying a relatively small patient cohort
compared to n > 200 for studies showing an effect of these
factors on the response to ADT [18]. The presence of nodal or
distant metastasis at diagnosis and nPSA did predict CRPC,
which is in keeping with current accepted practice that
these are the best factors in predicting response to ADT. A
limitation of our study is the relatively low number of
patients (n = 61). However, inclusion criteria were limited
to patients with MRI due to superior soft tissue contrast and
delineation of the PPFV compared with computed tomog-
raphy which is more commonly performed in advanced
disease. Body weight and waist circumference are highly
correlated (rs = 0.76, p < 0.0001 Spearman’s rank correla-
tion), therefore colinearity interactions are a limitation of
the Cox proportional hazards model including both factors.
4.2. Future development of PPFV as a biomarker for CRPC
MRI measured PPFV significantly improves the AUC of the
multivariate model of factors which can be known prior to
ADT (excluding nPSA, as this can only be determined after
ADT; Fig. 3). This suggests that the addition of PPFV mea-
surement can be considered a useful biomarker of CRPC. The
CHAARTED and STAMPEDE trials reported survival benefits
of upfront chemo-hormonal therapy [5], but a key unmet
clinical need remains in identifying patients who are likely
to respond poorly to ADT and thus have the greatest benefit
from upfront combined therapy prior to the development
of CRPC.
The technique described provides an accessible and
quick way to measure PPFV with acceptable interobserver
agreement as well as good intraclass correlation. Future
automated image analysis may reduce observer related
variation in PPFV measurement. Our study suggests a
relationship comparative to a dose response between
the PPFV and tumour response to ADT. This is consistent
with an important physiological role of the PPF in disease
progression to CRPC. Besides the CCL7/CCR3 cytokine axis,
other PPF-derived factors may also contribute to the local
macro-environment to support PC progression including
resistance to ADT [22].
5. Conclusions
Measurement of PPFV identifies patients at risk of biochem-
ical relapse before commencing ADT. Current knowledge
suggests that PPF contributes to the local tumour-promot-
ing macro-environment, and PPFV may be considered a
biomarker of such biological effects on tumours.
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